BridgeMD
ELIPS-Trial
EU CTIS ID: 2025-523151-66-00
What this study is testing
The aim of this study is to investigate whether the early administration of lyophilized plasma in the emergency room represents a better alternative to conventional crystalloid infusion solutions for patients in hemorrhagic shock. We hypothesize that lyophilized plasma, due to its significantly shorter application time (lyophilized plasma: 6.5 minutes; conventional plasma: approximately 30–45 minutes), its positive effects on the endothelium, and its sustained volume effect, leads to faster hemodynamic stabilization. The normalization of lactate levels (< 2 mmol/L) will be used as a surrogate parameter for this. Furthermore, we expect that the use of lyophilized plasma will significantly reduce the required amount of crystalloid infusion solutions, thereby avoiding potential side effects associated with volume overload.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 18 years of age or older; Patient in impending or hemorrhagic shock; Definition of hemorrhagic shock in this study: Obvious or suspected blood loss Systolic arterial blood pressure ≤90 mmHg or arterial hypotension requiring vasopressor administration Serum lactate concentration ≥2 mmol/L
You likely can't join if
- Initial activation of the massive transfusion protocol upon the patient's arrival in the emergency room Known, IgA deficiency, Hypersensitivity to plasma, Pregnancy or breastfeeding
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.